3 Roche Companies Hope to Make Clinical Trials More Efficient

Three companies under the Roche umbrella are looking to shake up the way clinical trials are conducted and better understand the patient journey during these studies. To this end, Flatiron Health, Foundation Medicine, and Genentech have launched the Prospective Clinico-Genomic (PCG) feasibility study. The trial will pilot the use of a technology-enabled prospective data collection platform to facilitate, streamline, and simplify the execution of clinical trials for patients living with advanced lung cancer. About 1,000 patients will be enrolled in PCG, which has a secondary aim to better understand how genomic changes in a patient’s tumor might predict response or impact resistance to treatment in people diagnosed with metastatic non-small cell lung cancer or extensive-stage small cell lung cancer by a linked data- and bio-repository. “Doing something in the space of prospective clinical studies is something that Flatiron has been thinking about for a long time,” Dr. Bobby Green, CMO, Flatiron, told MD+DI on Monday. “I think the partnership has worked well because we’re all sort of bringing different areas of expertise to the table.” Flatiron specializes in data collection and participates in the oncology-specific electronic health records-market. The New York-based company was acquired by Roche in a transaction valued at $1.9 billion in 2018. In that same year, Roche a...
Source: MDDI - Category: Medical Devices Authors: Tags: Business IVD Source Type: news